More Gene Mutations Drive Cancer Than Previously Thought
Featured ArticleMain Category: Genetics
Also Included In: Cancer / Oncology
Article Date: 08 Mar 2007 - 8:00 PDT
| Patient / Public: | ![]() |
4.4 (81 votes) |
| Healthcare Prof: | ![]() |
4.27 (15 votes) |
| Article Opinions: | 1 posts |
Scientists surveying the human genome have found that many more gene mutations drive the development of cancer than previously thought.
The survey is reported in the journal Nature.
In the largest survey of its kind, an international team comprising over 60 scientists from the UK, Hong Kong, the Netherlands, Belgium, USA and Australia, working for the Cancer Genome Project, examined more than 500 genes and 200 cancers and sequenced more than 250 million letters of DNA code.
They found about 120 new genes that drive the development of cancer cells.
All cancers are thought to be caused by gene mutations. Genes control the behaviour of cells, for example they tell them when to divide and when to die; thus abnormal genes either issue faulty instructions or the correct instructions at the wrong time or both, which leads to abnormal cell development and cancer.
Michael Stratton from the Wellcome Trust's Sanger Institute in Cambridge, UK, and one of the survey team leaders said "This is a lot more cancer genes than we expected to find."
The survey also discovered that two types of gene mutation are involved in cancer: driver and passenger. The driver mutations are thought to drive the rampant cell growth that causes cancer, while the passenger ones, which exist in much larger numbers, just go along for the ride.
Of the 1,000 cancer-specific mutations found, the team believes that about 150 of them are driver genes.
It is not easy to spot the difference between a driver and passenger gene, something this survey suggests will pose a great challenge for scientists.
Dr Andy Futreal, co-leader of the Cancer Genome Project explained "It turns out that most mutations in cancers are passengers."
"However, buried amongst them are much larger numbers of driver mutations than was previously anticipated. This suggests that many more genes contribute to cancer development than was thought," he added.
The types of genes that Futreal and his colleagues investigated are known as kinase genes. They have been linked with cancer development before. These protein genes act like relays, switching different types of cell behaviour on and off.
One example of a kinase gene is the BRAF, which an earlier study showed to be mutated in 60 per cent of malignant melanomas. This led to the development of new drugs, now in clinical trials, to treat melanoma.
This broader survey covered a wider range of the more common types of cancer, including breast, lung, colorectal and stomach cancers.
The researchers also found that a particular group of kinase genes "involved in the Fibroblast Growth Factor Receptor signalling pathway was hit much more than we expected, particularly in colorectal cancers," said Dr Futreal.
The survey also showed that buried inside each mutation are important coded messages, and that the type of mutation varied widely between different cancer types. This suggests that in some cases the process of mutation begins decades before the cancer presents itself.
It is as though gene mutations are "archeological sites" where written inside the DNA of each cell is a historical coded pattern that reveals the original cause of the cancer. In some cases the code can be deciphered, for instance damage from UV radiation or sunlight, or carcinogens in tobacco smoke, but in other cases the code is too hard to crack, which means more research effort is needed to unravel their mysteries.
"This study vindicates all of the effort that went into the Human Genome Project," said Dr Mark Walport, Director of the Wellcome Trust, the largest independent charity in the UK and the second largest medical research charity in the world, and the sponsors of the survey.
"Understanding the mutations that cause cancer is crucial in order to develop accurately targeted treatments," added Dr Walport.
"Patterns of somatic mutation in human cancer genomes."
Christopher Greenman, Philip Stephens, Raffaella Smith, Gillian L. Dalgliesh, Christopher Hunter, Graham Bignell, Helen Davies, Jon Teague, Adam Butler, Claire Stevens, Sarah Edkins, Sarah O'Meara, Imre Vastrik, Esther E. Schmidt, Tim Avis, Syd Barthorpe, Gurpreet Bhamra, Gemma Buck, Bhudipa Choudhury, Jody Clements, Jennifer Cole, Ed Dicks, Simon Forbes, Kris Gray, Kelly Halliday, Rachel Harrison, Katy Hills, Jon Hinton, Andy Jenkinson, David Jones, Andy Menzies, Tatiana Mironenko, Janet Perry, Keiran Raine, Dave Richardson, Rebecca Shepherd, Alexandra Small, Calli Tofts, Jennifer Varian, Tony Webb, Sofie West, Sara Widaa, Andy Yates, Daniel P. Cahill, David N. Louis, Peter Goldstraw, Andrew G. Nicholson, Francis Brasseur, Leendert Looijenga, Barbara L. Weber, Yoke-Eng Chiew, Anna deFazio, Mel F. Greaves, Anthony R. Green, Peter Campbell, Ewan Birney, Douglas F. Easton, Georgia Chenevix-Trench, Min-Han Tan, Sok Kean Khoo, Bin Tean Teh, Siu Tsan Yuen, Suet Yi Leung, Richard Wooster, P. Andrew Futreal and Michael R. Stratton.
Nature 446, 153-158 (8 March 2007)
doi:10.1038/nature05610
Click here for Abstract.
Click here for Catalogue of Somatic Mutations in Cancer, COSMIC (Wellcome Trust, Sanger Institute).
Written by: Catharine Paddock
Writer: Medical News Today
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/articles/64804.php>
APA
http://www.medicalnewstoday.com/articles/64804.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Gene Mutations And The Development Of Cancer Treatment
posted by Gregory D. Pawelski on 8 Mar 2007 at 5:09 pmIf you take 1,007 mutations in kinase genes alone, which are putatively associated with cancer, and try to figure out how many combinations of these mutations one could have, and then consider that mutations are only the beginning because it depends on the factors which regulate those genes, and how much the genes are expressed or repressed, and how all those things interact with all the other things which are going on, you have a pretty major challenge if you want to build a model of the cancer cell from the bottom up.
There are wonderful models of cardiovascular disease, kidney disease, stroke, infectious disease, musuloskeletal disease, etc. These models are much more complicated than cell culture and consist of things like guinea pigs, rats, dogs, hearts, aortas, kidneys and other medical procedures which work on intact systems, as opposed to isolated genes. And yet, intact human cancer cells were abandoned as a model system because they were deemed to be too complicated twenty years ago.
And tissue culture methods have made gene therapy possible. The ability to transfect cultured cells with DNA gene sequences has allowed scientists to assign functions to different genes and understand the mechanisms that activate or redress their function. The interaction between cell biology and genetics gave birth to molecular biology. Without cell culture, gene therapy would be beyond imagination.
Dr. Len Lichtenfeld says "We're going to be able to take a cancer specimen, analyze it, and follow those genetic changes that influence particular pathways, then we'll use one, two, three or more targeted therapies, perhaps simultaneously, and be able to completely interrupt the flow of the cancer process."
According to Dr. Arny Glazier, Cure: Scientific, Social and Organizational Requirements for the Specific Cure of Cancer, "the consistent and specific cure or control of cancer will require multiple drugs administered in combination targeted to abnormal patterns of normal cellular machinery that effect or reflect malignant behavior. Finding the 'patterns' of malignant cells and developing a set of 5 to10 drugs in order to cure or control cancer."
Dr. Glazier has reminded us that "one of the weaknesses of the existing organizational structure for cancer research is the reluctance to address multiple design features concurrently. Multi-dimensional problems require multi-dimensional solutions and coordinated team efforts." He certainly has it pegged.
Cell culture assays tests with cell-death endpoints are the Rosetta Stone which allows for identification of clinically relevant gene expression patterns which correlate with clinical drug resistance and sensitivity for different drugs in specific diseases. There is no single gene whose expression accurately predicts therapy outcome, emphasizing that cancer is a complex disease and needs to be attacked on many fronts.
A number of cell culture assay labs across the country have data from tens of thousands of fresh human tumor specimens, representing virtually all types of human solid and hematologic neoplasms. Cell culture assay labs have the database necessary to define sensitivity and resistance for virtually all of the currently available drugs in virtually all types of human solid and hematologic neoplasms.
I believe that improving cancer patient diagnosis and treatment through a combination of cellular and gene-based testing will offer predictive insight into the nature of an individual's particular cancer and enable oncologists to prescribe treatment more in keeping with the heterogeneity of the disease.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



